Journal: Frontiers in Oncology

Article Title: LPCAT1 as a prognostic biomarker and risk indicator for hepatocellular carcinoma: insights into genes related to lipid metabolism

doi: 10.3389/fonc.2026.1707270

Figure Lengend Snippet: LPCAT1 is upregulated in HCC and shows coordinated associations with ICB activity and immune-stromal infiltration. (A–C) Association of LPCAT1 mRNAexpression levels with advanced T stage (A) , TNM stage (B) , and histologic grade (C) in the TCGA-LIHC cohort. (D, E) GSEA for samples with highLPCAT1 expression (D) and low expression (E) . (F) IHC shows stronger LPCAT1 protein in tumor tissue than in adjacent non-tumor tissue. Scalebar:100mm. (G) LPCAT1 IHC staining was stronger in TNM stage III than in stage I tumors. Scale bar:100mm. (H) Box plot showed the ratio differentiation of 21 kinds of immune cells between LIHC tumor samples with low or high LPCAT1 expression relative to the median of LPCAT1 expression level. P values were adjusted for multiple comparisons using the Benjamini-Hochberg method. **Adjusted p < 0.01, ***adjusted p < 0.001. (I) Immune checkpoint genes expression levels in the high and low LPCAT1 expression in TCGA. **p < 0.01; ***p < 0.001.

Article Snippet: The antibodies employed were sourced from these suppliers: LPCAT1 (1:5000, 66044-1-Ig, Proteintech), β-actin (1:20000, AC038, Abclonal).

Techniques: Activity Assay, Expressing, Immunohistochemistry

Journal: Frontiers in Oncology

Article Title: LPCAT1 as a prognostic biomarker and risk indicator for hepatocellular carcinoma: insights into genes related to lipid metabolism

doi: 10.3389/fonc.2026.1707270

Figure Lengend Snippet: LPCAT1 drives HCC progression and confers therapeutic vulnerability via high-affinity interactions. (A) Western blot validation of LPCAT1 over-expression. (B) EdU proliferation assay showing increased DNA replication in LPCAT1-overexpressing cells. Scale bar:200μm (C) Colony formation assay demonstrating enhanced clonogenic capacity post-LPCAT1 over-expression. Scale bar: 200μm. (D) Wound healing assay was performed to evaluate the cell migration of LPCAT1-overexpressed Hepa1–6 cells. Scale bar: 100μm. (E, F) Transwell assays with/without matrigel coating for migration (E) and invasion (F) quantification. Scale bar:100μm. (G) The docking conformation and interaction force analysis of LPCAT1. *p < 0.05; **p < 0.01; ***p < 0.001.

Article Snippet: The antibodies employed were sourced from these suppliers: LPCAT1 (1:5000, 66044-1-Ig, Proteintech), β-actin (1:20000, AC038, Abclonal).

Techniques: Western Blot, Biomarker Discovery, Over Expression, Proliferation Assay, Colony Assay, Wound Healing Assay, Migration

Journal: Frontiers in Oncology

Article Title: LPCAT1 as a prognostic biomarker and risk indicator for hepatocellular carcinoma: insights into genes related to lipid metabolism

doi: 10.3389/fonc.2026.1707270

Figure Lengend Snippet: Structural dynamics of LPCAT1-kinase inhibitor complexes. (A-C) RMSD plots for (A) sorafenib, (B) lenvatinib, and (C) regorafenib complexes. (D-F) RMSF of LPCAT1 in complex with (D) sorafenib, (E) lenvatinib, and (F) regorafenib. (G-I) Ligand RMSF for (G) sorafenib, (H) lenvatinib, and (I) regorafenib. (J-L) Secondary structure evolution of LPCAT1 bound to (J) sorafenib, (K) lenvatinib, and (L) regorafenib.

Article Snippet: The antibodies employed were sourced from these suppliers: LPCAT1 (1:5000, 66044-1-Ig, Proteintech), β-actin (1:20000, AC038, Abclonal).

Techniques:

Journal: Frontiers in Oncology

Article Title: LPCAT1 as a prognostic biomarker and risk indicator for hepatocellular carcinoma: insights into genes related to lipid metabolism

doi: 10.3389/fonc.2026.1707270

Figure Lengend Snippet: Interaction landscapes and binding metrics. (A–C) Sorafenib binding mode: (A) Interaction types between sorafenib and LPCAT1. (B) TRP163 distance. (C) PHE513 distance. (D–F) Lenvatinib interaction dynamics: (D) Interaction types between lenvatinib and LPCAT1. (E) CYS514 distance. (F) TRP247 distance. (G–I) regorafenib interaction dynamics: (G) Interaction types between regorafenib and LPCAT1. (H) PHE206 distance. (I) ARG183 distance.

Article Snippet: The antibodies employed were sourced from these suppliers: LPCAT1 (1:5000, 66044-1-Ig, Proteintech), β-actin (1:20000, AC038, Abclonal).

Techniques: Binding Assay

Journal: Frontiers in Oncology

Article Title: LPCAT1 as a prognostic biomarker and risk indicator for hepatocellular carcinoma: insights into genes related to lipid metabolism

doi: 10.3389/fonc.2026.1707270

Figure Lengend Snippet: Interaction landscapes and binding metrics. (A–C) RMSD plots for (A) PD1-LPCAT1, (B) PDL1-LPCAT1, and (C) CTLA4-LPCAT1. (D–F) Interface residue RMSF for (D) PD1-LPCAT1, (E) PDL1-LPCAT1, and (F) CTLA4-LPCAT1. (G–I) Secondary structure conservation in (G) PD1, (H) PDL1, and (I) CTLA4 complexes.

Article Snippet: The antibodies employed were sourced from these suppliers: LPCAT1 (1:5000, 66044-1-Ig, Proteintech), β-actin (1:20000, AC038, Abclonal).

Techniques: Binding Assay, Residue

Journal: Cell metabolism

Article Title: Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling

doi: 10.1016/j.cmet.2019.06.014

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Mouse Monoclonal anti-LPCAT1, Clone 8B6E9 (WB 1:10000) , Proteintech , Cat#66044–1-lg; RRID:AB_11045658.

Techniques: Recombinant, Membrane, Transfection, SYBR Green Assay, Bicinchoninic Acid Protein Assay, Negative Control, Empire Assay, Plasmid Preparation, shRNA, Control, Sequencing, Software